ZA201801589B - Oncolytic adenovirus encoding a b7 protein - Google Patents

Oncolytic adenovirus encoding a b7 protein

Info

Publication number
ZA201801589B
ZA201801589B ZA201801589A ZA201801589A ZA201801589B ZA 201801589 B ZA201801589 B ZA 201801589B ZA 201801589 A ZA201801589 A ZA 201801589A ZA 201801589 A ZA201801589 A ZA 201801589A ZA 201801589 B ZA201801589 B ZA 201801589B
Authority
ZA
South Africa
Prior art keywords
protein
oncolytic adenovirus
adenovirus encoding
encoding
oncolytic
Prior art date
Application number
ZA201801589A
Other languages
English (en)
Inventor
Brian Robert Champion
Bromley, (Né Brown) Alice Claire Noel
Original Assignee
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507419.8A external-priority patent/GB201507419D0/en
Priority claimed from GBGB1516936.0A external-priority patent/GB201516936D0/en
Priority claimed from GBGB1522013.0A external-priority patent/GB201522013D0/en
Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd
Publication of ZA201801589B publication Critical patent/ZA201801589B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA201801589A 2015-04-30 2018-03-07 Oncolytic adenovirus encoding a b7 protein ZA201801589B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1507419.8A GB201507419D0 (en) 2015-04-30 2015-04-30 Virus
GBGB1516936.0A GB201516936D0 (en) 2015-09-24 2015-09-24 Virus
GBGB1522013.0A GB201522013D0 (en) 2015-12-14 2015-12-14 Virus

Publications (1)

Publication Number Publication Date
ZA201801589B true ZA201801589B (en) 2019-10-30

Family

ID=56008588

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA201801589A ZA201801589B (en) 2015-04-30 2018-03-07 Oncolytic adenovirus encoding a b7 protein

Country Status (31)

Country Link
US (6) US11000559B2 (cg-RX-API-DMAC7.html)
EP (2) EP3288573B1 (cg-RX-API-DMAC7.html)
JP (3) JP6931229B2 (cg-RX-API-DMAC7.html)
KR (4) KR20250134212A (cg-RX-API-DMAC7.html)
CN (2) CN107690479B (cg-RX-API-DMAC7.html)
AU (3) AU2016256582B2 (cg-RX-API-DMAC7.html)
BR (2) BR122018004815A2 (cg-RX-API-DMAC7.html)
CA (1) CA2984038C (cg-RX-API-DMAC7.html)
CL (2) CL2017002731A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017010831A2 (cg-RX-API-DMAC7.html)
CY (1) CY1122833T1 (cg-RX-API-DMAC7.html)
DK (1) DK3288573T3 (cg-RX-API-DMAC7.html)
EA (1) EA037611B1 (cg-RX-API-DMAC7.html)
ES (1) ES2780366T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200439T1 (cg-RX-API-DMAC7.html)
HU (1) HUE048320T2 (cg-RX-API-DMAC7.html)
IL (3) IL284375B (cg-RX-API-DMAC7.html)
LT (1) LT3288573T (cg-RX-API-DMAC7.html)
MX (1) MX2017013684A (cg-RX-API-DMAC7.html)
MY (1) MY183703A (cg-RX-API-DMAC7.html)
PE (2) PE20181140A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501942A1 (cg-RX-API-DMAC7.html)
PL (1) PL3288573T3 (cg-RX-API-DMAC7.html)
PT (1) PT3288573T (cg-RX-API-DMAC7.html)
RS (1) RS60105B1 (cg-RX-API-DMAC7.html)
SA (2) SA520412637B1 (cg-RX-API-DMAC7.html)
SG (3) SG11201708604TA (cg-RX-API-DMAC7.html)
SI (1) SI3288573T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000222T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016174200A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201801589B (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015030881A2 (pt) 2013-06-14 2017-10-24 Psioxus Theraupeutics Ltd “regime de dosagem e formulações para adenovírus de tipo b”
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
NO3021859T3 (cg-RX-API-DMAC7.html) 2013-10-25 2018-04-28
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
EA037611B1 (ru) 2015-04-30 2021-04-21 Псайоксус Терапьютикс Лимитед Онколитический аденовирус, кодирующий белок b7
MX2018005517A (es) 2015-11-02 2018-11-09 Five Prime Therapeutics Inc Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
WO2017103291A1 (en) * 2015-12-17 2017-06-22 Psioxus Therapeutics Limited Virus encoding an anti-tcr-complex antibody or fragment
EP4190906B1 (en) * 2016-03-31 2025-08-20 The European Molecular Biology Laboratory Engineered polypeptides derived from adenoviral fibre protein and vlps containing the polypeptides
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
SG11201901716TA (en) 2016-08-29 2019-03-28 Psioxus Therapeutics Ltd Adenovirus armed with bispecific t cell engager (bite)
ES2981703T3 (es) 2016-09-02 2024-10-10 Lentigen Tech Inc Composiciones y métodos para tratar cáncer con DuoCars
MX2019003546A (es) * 2016-09-27 2019-09-19 Sator Therapeutics LLC Virus oncoliticos optimizados y usos de los mismos.
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
CN110520438A (zh) 2017-02-03 2019-11-29 匹兹堡大学联邦系统高等教育 溶瘤病毒疗法
EP3628070B1 (en) 2017-04-28 2021-09-08 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides for use in increasing central memory t cells
WO2018218151A1 (en) * 2017-05-25 2018-11-29 University Of Central Florida Research Foundation, Inc. Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
US11253608B2 (en) 2017-05-26 2022-02-22 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes
JP7394628B2 (ja) 2017-06-01 2023-12-08 アカミス バイオ リミテッド 腫瘍溶解性ウイルスおよび方法
WO2019147921A1 (en) * 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
WO2019173334A1 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
CN111989397A (zh) * 2018-03-30 2020-11-24 藤堂具纪 肿胀发生抑制型溶瘤病毒
JP2022502074A (ja) * 2018-09-10 2022-01-11 ジェネセイル バイオテック（シャンハイ）カンパニー リミテッド 改変された腫瘍溶解性ウイルス、組成物、およびその使用
BR112021017551A2 (pt) * 2019-03-05 2021-11-09 Amgen Inc Uso de vírus oncolíticos para o tratamento de câncer
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
WO2020230838A1 (ja) * 2019-05-14 2020-11-19 オンコリスバイオファーマ株式会社 腫瘍組織に腫瘍溶解ウイルスを投与する方法、及び投与用デバイス
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
JP7697147B2 (ja) * 2021-06-03 2025-06-23 上▲海▼允英生物医▲薬▼科技有限公司 腫瘍溶解性ウイルスベクターおよびその適用
WO2023049852A1 (en) 2021-09-23 2023-03-30 Sagittarius Bio, Inc. Adenoviruses and methods for using adenoviruses
WO2023180527A1 (en) * 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
CZ287157B6 (en) 1993-07-13 2000-10-11 Rhone Poulenc Rorer Sa Defective recombinant adenovirus and pharmaceutical preparation in which said adenovirus is comprised
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
US6420524B1 (en) 1997-02-20 2002-07-16 Johns Hopkins University School Of Medicine Gain of function mutations in ATP-dependent transposition proteins
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
WO2000015823A1 (en) 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus
CA2354024C (en) * 1998-12-09 2009-12-22 Jeffrey Schlom A recombinant vector expressing multiple costimulatory molecules and uses thereof
DK1550722T3 (da) 1999-05-17 2007-10-08 Crucell Holland Bv Rekombinant human adenovirus serotype 35
AU5464000A (en) 1999-06-01 2000-12-18 University Of Washington Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
ES2254359T3 (es) * 2000-01-21 2006-06-16 Biovex Limited Cepa viral para el tratamiento oncolitico de canceres.
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
AU2001265154A1 (en) 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
EP1348030B1 (en) 2001-01-04 2009-11-25 Wadell, Göran Viral vector for gene therapy
US20050175589A1 (en) * 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
EP1470233A1 (en) 2002-02-01 2004-10-27 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
AU2003223775A1 (en) 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
CN1705740B (zh) * 2002-10-15 2013-07-24 佩尔·松内·霍尔姆 具有反向基因表达的腺病毒及其应用
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
WO2005010149A2 (en) 2003-07-18 2005-02-03 Onyx Pharmaceuticals, Inc. Subgroup b adenoviral vectors for treating disease
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
DE602005025340D1 (de) 2004-05-26 2011-01-27 Bayer Schering Pharma Ag Chimäre adenoviren zur verwendung in der krebsbehandlung
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CN101068933A (zh) * 2004-08-25 2007-11-07 细胞基因系统有限公司 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体
JP2008511336A (ja) * 2004-09-01 2008-04-17 アメリカ合衆国 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
US20090208924A1 (en) 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
BRPI0615400A2 (pt) 2005-08-31 2011-05-17 Genvec Inc vacinas para malária baseadas em vetor adenoviral
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
WO2008080003A2 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
WO2009143610A1 (en) 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
CN101381742A (zh) * 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2011043719A1 (en) * 2009-10-05 2011-04-14 Ya-Fang Mei Replicating viral vectors for gene therapy
WO2012024351A2 (en) 2010-08-16 2012-02-23 Salk Institute For Biological Studies Adenoviral assembly method
CA2812096A1 (en) * 2010-09-24 2012-03-29 Oncos Therapeutics Oy Adenoviral vectors and methods and uses related thereto
CA2812093A1 (en) 2010-09-24 2012-03-29 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
EP2780020A4 (en) 2011-11-14 2016-03-02 Regenerative Sciences Llc SUSPENDED PARTICLE DISTRIBUTION SYSTEMS AND METHODS
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
CN105407902A (zh) 2013-03-05 2016-03-16 贝勒医学院 溶瘤病毒
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
NO3021859T3 (cg-RX-API-DMAC7.html) * 2013-10-25 2018-04-28
AU2014352749A1 (en) 2013-11-22 2016-06-09 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) * 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
US11485791B2 (en) 2015-03-17 2022-11-01 Tilt Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies
EA037611B1 (ru) 2015-04-30 2021-04-21 Псайоксус Терапьютикс Лимитед Онколитический аденовирус, кодирующий белок b7
WO2017103291A1 (en) 2015-12-17 2017-06-22 Psioxus Therapeutics Limited Virus encoding an anti-tcr-complex antibody or fragment
WO2017161360A2 (en) 2016-03-18 2017-09-21 Nant Holdings Ip, Llc Multimodal vector for dendritic cell infection
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
SG11201901716TA (en) 2016-08-29 2019-03-28 Psioxus Therapeutics Ltd Adenovirus armed with bispecific t cell engager (bite)
EP3529361B1 (en) 2016-10-20 2021-03-24 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
JP7394628B2 (ja) * 2017-06-01 2023-12-08 アカミス バイオ リミテッド 腫瘍溶解性ウイルスおよび方法
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
HK1249009A1 (en) 2018-10-26
SA520412637B1 (ar) 2022-03-01
KR102643574B1 (ko) 2024-03-06
IL255286A0 (en) 2017-12-31
PT3288573T (pt) 2020-03-25
KR20250134212A (ko) 2025-09-09
US10849945B2 (en) 2020-12-01
KR102854512B1 (ko) 2025-09-04
PE20180241A1 (es) 2018-01-31
US10548929B2 (en) 2020-02-04
KR20240032177A (ko) 2024-03-08
SG10201901482XA (en) 2019-03-28
CL2017002731A1 (es) 2018-06-08
SMT202000222T1 (it) 2020-05-08
EA037611B1 (ru) 2021-04-21
IL255286B (en) 2021-01-31
WO2016174200A1 (en) 2016-11-03
KR20180022638A (ko) 2018-03-06
AU2018201446B2 (en) 2020-05-28
PE20181140A1 (es) 2018-07-17
PL3288573T3 (pl) 2020-05-18
IL258044A (en) 2018-05-31
SI3288573T1 (sl) 2020-06-30
AU2016256582B2 (en) 2020-10-29
SG11201708604TA (en) 2017-11-29
US20180140649A1 (en) 2018-05-24
BR122018004815A2 (pt) 2019-09-10
CN108396015B (zh) 2022-02-18
CL2018000587A1 (es) 2018-08-10
PH12017501942A1 (en) 2018-03-19
RS60105B1 (sr) 2020-05-29
US11000559B2 (en) 2021-05-11
JP6931229B2 (ja) 2021-09-01
EP3391892A1 (en) 2018-10-24
CN108396015A (zh) 2018-08-14
EA201791971A1 (ru) 2018-04-30
US10322152B2 (en) 2019-06-18
JP2018139586A (ja) 2018-09-13
BR112017023171A2 (pt) 2018-07-17
JP6928380B2 (ja) 2021-09-01
AU2016256582A1 (en) 2017-11-16
ES2780366T3 (es) 2020-08-25
MX2017013684A (es) 2018-08-28
AU2016256582A8 (en) 2018-01-18
CA2984038A1 (en) 2016-11-03
CO2017010831A2 (es) 2018-02-28
CA2984038C (en) 2023-01-03
CN107690479B (zh) 2022-02-18
EP3288573B1 (en) 2020-02-12
HUE048320T2 (hu) 2020-07-28
EP3288573A1 (en) 2018-03-07
JP2018514199A (ja) 2018-06-07
SG10201803081TA (en) 2018-06-28
JP7162929B2 (ja) 2022-10-31
JP2021176339A (ja) 2021-11-11
CN107690479A (zh) 2018-02-13
US20180042973A1 (en) 2018-02-15
IL284375A (en) 2021-07-29
MY183703A (en) 2021-03-09
DK3288573T3 (da) 2020-03-16
US20170266243A1 (en) 2017-09-21
AU2020223665A1 (en) 2020-09-10
IL284375B (en) 2022-07-01
AU2018201446A1 (en) 2018-03-29
KR20180118249A (ko) 2018-10-30
US20170056458A1 (en) 2017-03-02
CY1122833T1 (el) 2021-05-05
US20190076493A1 (en) 2019-03-14
LT3288573T (lt) 2020-03-25
US10124028B2 (en) 2018-11-13
SA517390260B1 (ar) 2021-11-10
HRP20200439T1 (hr) 2020-06-12
IL258044B (en) 2021-07-29
US20210338753A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
IL258044A (en) Oncolytic adenovirus encoding the b7 protein
IL260027A (en) A group b adenovirus that encodes an anti-tcr-complex antibody or particle
ZA201802261B (en) Polypeptides
PL3659614T3 (pl) Onkolityczny wirus krowianki
IL254577A0 (en) polypeptides
GB201713765D0 (en) Modified adenovirus
GB201409634D0 (en) Intra block copy mode encoding choice
PL3303290T3 (pl) Modulatory ROR-gamma
PL3303291T3 (pl) Modulatory ROR-gamma
PL3303293T3 (pl) Modulatory ROR-gamma
ZA201704366B (en) Il-17a-binding polypeptides
SG11201706882VA (en) Polypeptides
GB201418562D0 (en) Peptides
PL3319942T3 (pl) MODULATORY ROR-GAMMA (RORγ)
GB201417535D0 (en) Adapting encoding properties
IL267267A (en) Vibration sensing system with wavelength encoding
EP3239962A4 (en) Encoding device
GB2539417B (en) Optimized multi-view image encoding
GB201520655D0 (en) Multi-mode sensor
GB201614607D0 (en) Modified adenovirus
GB201706219D0 (en) Modified adenovirus
GB201700663D0 (en) Modified adenovirus
GB201401159D0 (en) Adenovirus
GB201516655D0 (en) IX sensor
GB201502178D0 (en) Detecting polypeptides